Abstract
We report Ir-catalyzed, enantioselective allylic substitution reactions of unstabilized silyl enolates derived from α,β-unsaturated ketones. Asymmetric allylic substitution of a variety of allylic carbonates with silyl enolates gave allylated products in 62–94% yield with 90–98% ee and >20:1 branched to linear selectivity. The synthetic utility of this method was illustrated by the short synthesis of an anti-cancer agent TEI-9826.
Keywords: asymmetric allylic substitution; unstabilized enolates; α, β-unsaturated ketones
The asymmetric alkylation of unstabilized ketone enolates is a long-standing synthetic challenge in organic chemistry.1 One classic approach involves the SAMP and RAMP2 chiral auxiliaries; a second, catalytic approach involves Pd-catalyzed decarboxylative allylation.3 Both of these approaches create products containing a stereocenter α to the carbonyl group. Methods for alkylation of enolates that form products containing a stereogenic center at the β position are challenging, in part, because of the difficulty in conducting nucleophilic substitution at a secondary position. One approach to address this synthetic problem involves Ir-catalyzed asymmetric allylic substitution.4 In contrast to the regioselectivity of Pd-catalyzed reactions,5 the Ir-catalyzed allylic substitution occurs at the more substituted position of an allyl electrophile and, therefore, creates a stereocenter at the position β to the carbonyl group in the product.6, 7
However, the scope of Ir-catalyzed allylic substitution reactions with unactivated, monocarbonyl enolates is limited. Most of the allylic substitution reactions with carbon nucleophiles have been conducted with stabilized enolates.8 The majority of reactions with unstabilized ketone enolates have been conducted with derivatives of acetophenone.9
α,β-Unsaturated ketones are valuable building blocks in organic synthesis because they contain two functional groups.1 Most transformations of this class of molecule exploit its electrophilicity. Reactions in which α,β-unsaturated ketones would act as the nucleophile are less common because the enolate can undergo aldol condensation or Michael additions with another α,β-unsaturated ketone. Consistent with this assertion, Ir-catalyzed asymmetric allylic substition has not been reported with enolates derived from α,β-unsaturated ketones. Nevertheless, such a transformation would be valuable because products generated from the allylic substitution of such a reagent contain three functional groups: an electron-deficient alkene, an electron-rich alkene and a carbonyl group. A set of orthogonal reactivities of these functional groups should allow the ketone products to undergo a variety of transformations to generate valuable intermediates.
We describe Ir-catalyzed enantioselective allylic substitution reactions with unstabilized silicon enolates derived from α,βunsaturated ketones that occur in good yields and high enantioselectivities with excellent branched to linear selectivities (Figure 1). The use of KF and 18-crown-6 as the additives is the key to the development of this reaction. Under these conditions, products from competing pathways derived from the electrophilicity of the starting or product ketone were not observed. The utility of this process was illustrated by the syntheses of syn- and anti-4-methyl-pentan-2-ols and the total synthesis of TEI-9826.
Figure 1.

Ir-Catalyzed Enantioselective Allylic Substitution of Silyl Enolates of α,β-Unsaturated Ketones
We initiated our studies to identify an appropriate activator for the reactions of methyl cinnamyl carbonate 1a with silyl enolate 2a in the presence of [Ir(COD)Cl]2 and the phosphoramidite ligand. Fluoride additives, such as KF, ZnF2 or CsF and ZnF2 have been shown to promote the α-arylation reactions of silyl ketene acetals and α-silyl nitriles, as well as the allylation of acetophenones.10 Therefore, we evaluated several fluoride salts as the additive for the allylic substitution reactions of 1a with 2a. Treatment of carbonate 1a (1 equiv) and silyl enolate 2a (2 equiv) with 2 mol % [Ir(COD)Cl]2 and 4 mol % (Ra,Rc,Rc)-L in the presence of KF (1 equiv) at 50 °C for 12 h, did not provide any of product 3a (entry 1, Table 1), and the reaction with ZnF2 as the additive also gave none of product 3a (entry 2, Table 1). The reaction with CsF (1 equiv) gave the allylated product 3a in only 16% yield (entry 3, Table 1). Even the reaction with CsF (0.4 equiv) and ZnF2 (1.5 equiv) together provided 3a in only 25% yield (entry 4, Table 1). We initially suspected that the low solubility of these metal fluoride salts in THF might be responsible for the low reactivity of silyl enolate 2a.11 However, the reactions with soluble fluoride salts, such as TASF or TBAT, led to the decomposition of the starting materials (entries 5–6, Table 1).
Table 1.
Evaluation of Reaction Conditions for the Ir-catalyzed Asymmetric Allylic Substitution of 1a with Silyl Enolate 2a.
| |||
|---|---|---|---|
| entry | conditions | yield | % ee |
| 1 | 1 equiv KF | N.R. | N.D. |
| 2 | 0.5 equiv ZnF2 | N.R. | N.D. |
| 3 | 1 equiv CsF | 16% | N.D. |
| 4 | 0.4 equiv CsF, 1.5 equiv ZnF2 | 25% | N.D. |
| 5 | 1 equiv TASF | decomp. | N.D. |
| 6 | 1 equiv TBAT | decomp. | N.D. |
| 7 | 1 equiv CsF, 1 equiv 18-crown-6 | decomp. | N.D. |
| 8 | 1 equiv KF, 1 equiv 18-crown-6 | 90% | 96% |
It is known that crown ethers have high binding affinities for alkali metal ions. We anticipated that the addition of crown ethers and fluoride salts as the additives might be beneficial to the reaction. Although the reaction with CsF (1 equiv) and 18-crown-6 (1 equiv) only led to the decomposition of the starting materials (entry 7, Table 1), the reaction with added KF (1 equiv) and 18-crown-6 (1 equiv) formed the desired product 3a in 90% yield with 96% ee and >20:1 branched to linear selectivity (entry 8, Table 1).
Table 2 shows the scope of allylic carbonate that undergoes the asymmetric allylation of carbonates 1 with silyl enolate 2a under the developed conditions (Table 2). In general, allylic substitution of a variety of substituted cinnamyl carbonates with 2a gave the allylation products 3a–h in high yield. Alkenyl- and alkyl-substituted allylic carbonates also reacted to provide the allylated products 3i–j in good yield. Although heteroaryl-substituted allylic carbonates could potentially bind and thereby deactivate the catalyst, we found that allylic substitution of carbonates containing heteroaryl groups, such as the pyridyl or the furyl group, provided products 3k–l in 76–83% yield. In all cases, the allylation products were obtained with >90% ee and >20:1 branched to linear selectivities. Detectable amounts of products from diallylation were not formed from these reactions.
Table 2.
Scope of the Ir-catalyzed Asymmetric Allylation of Carbonates 1 with Silyl Enolate 2a.
|
(a) Reaction conditions: carbonate 1 (0.2 mmol, 1.0 equiv), silyl enol ether 2a (0.4 mmol, 2.0 equiv), [Ir(COD)Cl]2 (2 mol %), (Ra,Rc,Rc)-L (4 mol %), KF (1.0 equiv), 18-crown-6 (1.0 equiv), THF (0.4 mL), 50 °C, 12 h. (b) Branched to linear ratios (B:L) were determined by 1H NMR analysis of the crude reaction mixtures. (c) ee % were determined by chiral HPLC analysis.
Table 3 summarizes the scope of the silyl enolate that undergoes this substitution process. A range of silyl enolate nucleophiles with different substitution patterns at the olefin unit participated in the allylic substitution. These reactions proceeded with 91–97% ee and >20:1 branched to linear selectivities. For example, reactions of allylic carbonates with 4-methoxyphenyl or 2-thienyl-substituted enolates gave the allylation products 4a–f in 87–94% yield and 94–97% ee. Silyl enolates containing substituents at the α or β position or both also reacted to provide the allylation products 4g–k in 62–89% yield and 91–96% ee. The silyl enolate derived from β-lonone also reacted to give product 4l in 93% yield and 96% ee.
Table 3.
Scope of the Ir-catalyzed Asymmetric Allylation of Carbonates 1 with Silyl Enolates 2.
|
(a) Reaction conditions: carbonate 1 (0.2 mmol, 1.0 equiv), silyl enol ether 2 (0.4 mmol, 2.0 equiv), [Ir(COD)Cl]2 (2 mol %), (Ra,Rc,Rc)-L (4 mol %), KF (1.0 equiv), 18-crown-6 (1.0 equiv), THF (0.4 mL), 50 °C, 8–12 h. (b) Branched to linear ratios (B:L) were determined by 1H NMR analysis of the crude reaction mixtures. (c) ee % were determined by chiral HPLC analysis.
Diastereoselective allylation with chiral, nonracemic nucleophiles in the presence of enantiomerically pure catalysts is a useful approach to prepare products containing multiple stereocenters selectively. However, the inherent bias of substrates may affect the stereochemical outcome of these reactions. To investigate the diastereoselective allylation with enantioenriched nucleophiles, allylic substitution reactions of silyl enol ether 5 were conducted (Scheme 1). Allylation of methyl cinnamyl carbonate 1a with enolate 5 gave product 7 in 61% yield, although a significant amount of branched methoxy-ether byproduct was obtained (data not shown). However, when tert-butyl cinnamyl carbonate 6 was used instead of 1a, the ether byproduct was not observed. In the presence of [Ir(COD)Cl]2 and (R)-L, the reaction of carbonate 6 with enolate 5 gave allylation product 7 in 85% yield, >50:1 diastereoselectivity and >20:1 branched to linear selectivity. When [Ir(COD)Cl]2/(S)-L was used, product 8 was obtained in 83% yield with >50:1 diastereoselectivity and >20:1 branched to linear selectivity. The structures of 7 and 8 were confirmed by single crystal X-ray diffraction. These data demonstrated that double stereo-differentiating reactions of enantioenriched nucleophile 5 proceeded with complete catalyst control to give allylation products 7 and 8 with excellent diastereoselectivity.
Scheme 1.
Ir-catalyzed Diastereoselective Allylic Substitution of Silyl Enolate 5
syn- and anti-4-Methyl-pentan-2-ols are common structural motifs in many biologically active natural products.12 Asymmetric synthesis of these structural subunits, however, has been challenging.13 These motifs are typically prepared by a multi-step sequence starting with a component of the chiral pool (e.g. Roche ester).14 We envisioned that diastereoselective reduction of the ketone of the allylation product, such as 3j, could provide a simple means to synthesize either the syn- or anti- diastereomer.
As illustrated in Scheme 2, allylic substitution of methyl crotylcarbonate with enolate 10 provided ketone 11 in 81% yield, 95% ee and >20:1 branched selectivity. Reduction of ketone 11 with NaBH4/CeCl315 gave a 1:1 mixture of diastereomers 12 and 13, reflecting a lack of inherent stereochemical bias in the reduction reaction. When reduction of ketone 11 was conducted with the (R)-CBS catalyst,16 alcohol 12 was obtained in 73% yield and with 11:1 diastereoselectivity; when the reaction was conducted in the presence of the (S)-CBS catalyst, diastereomer 13 formed with similar yield and diastereoselectivity (69% yield, 10:1 d.r.). Compound 12 represents the C2–C10 fragment of spongidepsin.
Scheme 2.
Synthesis of syn- and anti-4-Methylpentan-2-ols
Prostaglandins are important natural products, which have anti-inflammatory, antiviral and antitumor activities.17 Because of their structural features and diverse biological activities, prostaglandins have been the subject of many synthetic studies.18 As depicted in Scheme 3, a common structural motif in many members in the prostaglandin family is an enantioenriched cyclopentenone unit; therefore, such cyclopentenones are valuable intermediates for the synthesis of prostaglandin natural products.19, 20 We envisioned that ring-closing metathesis21 of the products generated from the asymmetric allylic substitution (e.g. 3) would provide enantioenriched cyclopentenones (e.g. 14) that could provide the basis for modular syntheses of these prostaglandin natural products.
Scheme 3.
Enantioselective Synthesis of TEI-9826
One member of the prostaglandin family is TEI-9826.20 Recent studies have shown that, in addition to its neuroprotective activity, TEI-9826 has significant activity against a number of cancer lines, including in vivo activity against cis-platin-resistant tumors when it is integrated with a lipid microsphere.22
An enantioselective synthesis of TEI-9826 based on asymmetric allylic substitution is summarized in Scheme 3. Starting from silyl enol ether 15 (obtained in one step from commercially available 3-penten-2-one), asymmetric allylic substitution of carbonate 16 with 15 under the standard conditions gave product 17 in 85% yield, 95% ee and 11:1 branched to linear selectivity. Ring-closing metathesis of 17 with 3 mol % of Grubbs’ II catalyst 18 provided cyclopentenone 14 in 86% yield.21 Compound 14 was then converted into TEI-9826 in 73% yield using a three-step sequence: aldol condensation with aldehyde 19, mesylation of the resulting alcohol, and elimination of the mesylate with neutral Al2O3.23 By this strategy, TEI-9826 was prepared in six steps from commercially available starting materials. This synthesis of TEI-9826 is the shortest one reported to date.
In conclusion, we have developed Ir-catalyzed enantioselective allylic alkylation reactions of unstabilized silyl enolates derived from α,β-unsaturated ketones. By utilizing silyl enolate derivatives of α,β-unsaturated ketones in combination with fluoride and crown ether, we exploit their latent nucleophilicity, while avoiding side reactions that would arise from their inherent electrophilicity. These silyl enolates readily participate in asymmetric allylation to provide enantioenriched products containing a stereogenic center at the position β to the carbonyl group. The products of these reactions contain several functional groups that undergo orthogonal chemical reactions. The synthetic utility of such products was demonstrated by the synthesis of both syn- and anti-4-methyl-pentan-2-ols, as well as the synthesis of TEI-9826. Further studies of α,β–unsaturated carbonyl compounds are onging.
Supplementary Material
Acknowledgments
Financial support provided by the National Institutes of Health (GM-58108) is gratefully acknowledged. We thank Johnson-Matthey for gifts of [Ir(COD)Cl]2.
Footnotes
Supporting information for this article is available on the WWW under http://www.angewandte.org.
Publisher's Disclaimer: This PDF receipt will only be used as the basis for generating PubMed Central (PMC) documents. PMC documents will be made available for review after conversion. Any corrections that need to be made will be done at that time. No materials will be released to PMC without the approval of an author. Only the PMC documents will appear on PubMed Central -- this PDF Receipt will not appear on PubMed Central.
References
- 1.(a) Jacobsen EN, Pfaltz A, Yamamoto H. Comprehensive Asymmetric Catalysis I-III. Springer; Berlin: 1999. [Google Scholar]; (b) Ojima I. Catalytic Asymmetric Synthesis. 2. Wiley/VCH; New York: 2000. [Google Scholar]
- 2.(a) Enders D. In: Asymmetric Synthesis: Stereodifferentiating Addition Reactions, Part B. Morrison JD, editor. Vol. 3. Academic; Orlando, FL: 1984. p. 275. [Google Scholar]; (b) Enders D, Eichenauer H, Baus U, Schubert H, Kremer KAM. Tetrahedron. 1984;40:1345. [Google Scholar]; (c) Lim D, Coltart DM. Angew Chem, Int Ed. 2008;47:5207. doi: 10.1002/anie.200800848. [DOI] [PubMed] [Google Scholar]
- 3.(a) Trost BM, Xu J. J Am Chem Soc. 2005;127:17180. doi: 10.1021/ja055968f. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Trost BM, Xu J, Schmidt T. J Am Chem Soc. 2009;131:18343. doi: 10.1021/ja9053948. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Behenna DC, Stoltz BM. J Am Chem Soc. 2004;126:15044. doi: 10.1021/ja044812x. [DOI] [PubMed] [Google Scholar]
- 4.(a) Helmchen G, Dahnz A, Dubon P, Schelwies M, Weihofen R. Chem Commun. 2007:675. doi: 10.1039/b614169b. [DOI] [PubMed] [Google Scholar]; (b) Helmchen G. In: Iridium Complexes in Organic Synthesis. Oro LA, Claver C, editors. Wiley-VCH; Weinheim, Germany: 2009. p. 211. [Google Scholar]; (c) Hartwig JF, Pouy MJ. Top Organomet Chem. 2011;34:169. [Google Scholar]; (d) Liu WB, Xia JB, You SL. Top Organomet Chem. 2012;38:155. [Google Scholar]; (e) Tosatti P, Nelson A, Marsden SP. Org Biomol Chem. 2012;10:3147. doi: 10.1039/c2ob07086c. [DOI] [PubMed] [Google Scholar]
- 5.(a) Trost BM, Van Vranken DL. Chem Rev. 1996;96:395. doi: 10.1021/cr9409804. [DOI] [PubMed] [Google Scholar]; (b) Trost BM, Crawley ML. Chem Rev. 2003;103:2921. doi: 10.1021/cr020027w. [DOI] [PubMed] [Google Scholar]; (c) Lu Z, Ma S. Angew Chem, Int Ed. 2008;47:258. doi: 10.1002/anie.200605113. [DOI] [PubMed] [Google Scholar]; (d) Hong AY, Stoltz BM. Eur J Org Chem. 2013;14:2745. doi: 10.1002/ejoc.201201761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.(a) Takeuchi R, Kashio M. Angew Chem, Int Ed. 1997;36:263. [Google Scholar]; (b) Janssen JP, Helmchen G. Tetrahedron Lett. 1997;38:8025. [Google Scholar]; (c) Ohmura T, Hartwig JF. J Am Chem Soc. 2002;124:15164. doi: 10.1021/ja028614m. [DOI] [PubMed] [Google Scholar]; (d) Kiener CA, Shu C, Incarvito C, Hartwig JF. J Am Chem Soc. 2003;125:14272. doi: 10.1021/ja038319h. [DOI] [PubMed] [Google Scholar]
- 7.For recent developments, see: Chen W, Hartwig JF. J Am Chem Soc. 2012;134:15249. doi: 10.1021/ja306850b.Schafroth MA, Sarlah D, Krautwald S, Carreira EM. J Am Chem Soc. 2012;134:20276. doi: 10.1021/ja310386m.Hamilton JY, Sarlah D, Carreira EM. J Am Chem Soc. 2013;135:994. doi: 10.1021/ja311422z.Hamilton JY, Sarlah D, Carreira EM. Angew Chem, Int Ed. 2013;52:7532. doi: 10.1002/anie.201302731.Krautwald S, Sarlah D, Schafroth MA, Carreira EM. Science. 2013;340:1065. doi: 10.1126/science.1237068.Zhuo CX, Wu QF, Zhao Q, Xu QL, You SL. J Am Chem Soc. 2013;135:8169. doi: 10.1021/ja403535a.Hamilton JY, Sarlah D, Carreira EM. J Am Chem Soc. 2014;136:3006. doi: 10.1021/ja412962w.Krautwald S, Schafroth MA, Sarlah D, Carreira EM. J Am Chem Soc. 2014;136:3020. doi: 10.1021/ja5003247.
- 8.For selected recent examples, see: Kanayama T, Yoshida K, Miyabe H, Takemoto Y. Angew Chem, Int Ed. 2003;42:2054. doi: 10.1002/anie.200250654.Polet D, Rathgeb X, Falciola CA, Langlois JB, El HS, Alexakis A. Chem—Eur J. 2009;15:1205. doi: 10.1002/chem.200801879.Liu WB, Zheng C, Zhuo CX, Dai LX, You SL. J Am Chem Soc. 2012;134:4812. doi: 10.1021/ja210923k.Liu WB, Reeves CM, Virgil SC, Stoltz BM. J Am Chem Soc. 2013;135:10626. doi: 10.1021/ja4052075.Liu W-B, Reeves CM, Virgil SC, Stoltz BM. 2013;135:17298. doi: 10.1021/ja4097829.Chen W, Hartwig JF. J Am Chem Soc. 2013;135:2068. doi: 10.1021/ja311363a.Chen W, Hartwig JF. J Am Chem Soc. 2014;136:377. doi: 10.1021/ja410650e.
- 9.(a) Graening T, Hartwig JF. J Am Chem Soc. 2005;127:17192. doi: 10.1021/ja0566275. [DOI] [PubMed] [Google Scholar]; (b) Weix DJ, Hartwig JF. J Am Chem Soc. 2007;129:7720. doi: 10.1021/ja071455s. [DOI] [PubMed] [Google Scholar]; (c) He H, Zheng XJ, Li Y, Dai LX, You SL. Org Lett. 2007;9:4339. doi: 10.1021/ol7019394. [DOI] [PubMed] [Google Scholar]
- 10.(a) Hama T, Liu X, Culkin DA, Hartwig JF. J Am Chem Soc. 2003;125:11176. doi: 10.1021/ja036792p. [DOI] [PubMed] [Google Scholar]; (b) Wu L, Hartwig JF. J Am Chem Soc. 2005;127:15824. doi: 10.1021/ja053027x. [DOI] [PubMed] [Google Scholar]
- 11.The α-arylation reactions of silyl ketene acetals and α-silyl nitriles with KF or ZnF2 as the additive were conducted in DMF.
- 12.(a) Grassia A, Bruno I, Debitus C, Marzocco S, Pinto A, Gomez-Paloma L, Riccio R. Tetrahedron. 2001;57:6257. [Google Scholar]; (b) Wright AE, Botelho JC, Guzman E, Harmody D, Linley P, McCarthy PJ, Pitts TP, Pomponi SA, Reed JK. J Nat Prod. 2007;70:412. doi: 10.1021/np060597h. [DOI] [PubMed] [Google Scholar]
- 13.Lin H, Pei W, Wang H, Houk KN, Krauss IJ. J Am Chem Soc. 2013;135:82. doi: 10.1021/ja311061n. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.(a) Ferrié L, Reymond S, Capdevielle P, Cossy J. Org Lett. 2006;8:3441. doi: 10.1021/ol061029w. [DOI] [PubMed] [Google Scholar]; (b) Youngsaye W, Lowe JT, Pohlki F, Ralifo P, Panek JS. Angew Chem, Int Ed. 2007;46:9211. doi: 10.1002/anie.200704122. [DOI] [PubMed] [Google Scholar]
- 15.Luche JL. J Am Chem Soc. 1978;100:2226. [Google Scholar]
- 16.Corey EJ, Helal CJ. Angew Chem, Int Ed Engl. 1998;37:1986. doi: 10.1002/(SICI)1521-3773(19980817)37:15<1986::AID-ANIE1986>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
- 17.Roberts SM, Santoro M, Sickle E. J Chem Soc, Perkin Trans I. 2002:1735. [Google Scholar]
- 18.Das S, Chandrasekhar S, Yadav JS, Grée R. Chem Rev. 2007;107:3286. doi: 10.1021/cr068365a. [DOI] [PubMed] [Google Scholar]
- 19.Acharya HP, Kobayashi Y. Tetrahedron. 2006;62:3329. [Google Scholar]
- 20.(a) Sugiura S, Hazato A, Tanaka T, Okamura K, Bannai K, Manabe S, Kurozumi S, Noyori R. Chem Pharm Bull. 1985;33:4120. doi: 10.1248/cpb.33.4120. [DOI] [PubMed] [Google Scholar]; (b) Weaving R, Roulland E, Monneret C, Florent JC. Tetrahedron Lett. 2003;44:2579. [Google Scholar]; (c) Iqbal M, Evans P. Tetrahedron Lett. 2003;44:5741. [Google Scholar]; (d) Zurawinski R, Mikina M, Mikolajczyk M. Tetrahedron Asymm. 2010;21:2794. [Google Scholar]
- 21.(a) Scholl M, Ding S, Lee CW, Grubbs RH. Org Lett. 1999;1:953. doi: 10.1021/ol990909q. [DOI] [PubMed] [Google Scholar]; (b) Vougioukalakis GC, Grubbs RH. Chem Rev. 2010;110:1746. doi: 10.1021/cr9002424. [DOI] [PubMed] [Google Scholar]
- 22.(a) Sasaki H, Niimi S, Akiyama M, Tanaka T, Kurozumi S, Fukushima M. Cancer Res. 1999;59:3919. [PubMed] [Google Scholar]; (b) Fukushima S, Kishimoto S, Takeuchi Y, Fukushima M. Adv Drug Delivery Rev. 2000;45:65. doi: 10.1016/s0169-409x(00)00101-0. [DOI] [PubMed] [Google Scholar]; (c) Furuta K, Tomokiyo K, Satoh T, Watanabe Y, Suzuki M. ChemBioChem. 2000;1:283. doi: 10.1002/1439-7633(20001117)1:4<283::AID-CBIC283>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]; (d) Furuta K, Maeda M, Hirata Y, Shibata S, Kiuchi K, Suzuki M. Bioorg Med Chem Lett. 2007;17:5487. doi: 10.1016/j.bmcl.2006.12.004. [DOI] [PubMed] [Google Scholar]
- 23.Kobayashi Y, Murugesh MG, Nakano M, Takahisa E, Usmani SB, Ainai T. J Org Chem. 2002;67:7110. doi: 10.1021/jo020375y. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.



